Literature DB >> 19915801

Angiotensin II up-regulates CX3CR1 expression in THP-1 monocytes: impact on vascular inflammation and atherogenesis.

Stavros Apostolakis1, Zacharenia Vlata, Konstantina Vogiatzi, Elias Krambovitis, Demetrios A Spandidos.   

Abstract

The potential regulatory effect of angiotensins on circulating mononuclear cell activation and migration has not yet been thoroughly evaluated. Using flow cytometry we assessed the possible effect of angiotensin I and II on the expression of CX3CR1 and a single representative of each major chemokine family (CCR5 and CXCR4) in THP-1 monocytes, Jurcat T lymphocytes and primary monocytes-isolated from healthy donors. Fluorescence intensity and the rate of chemokine-positive cells was measured in naïve cells and cells treated with angiotensin I and II. Neither angiotensin I nor angiotensin II exhibited any effect on fluorescence intensity and the rate of CX3CR1-, CCR5- and CXCR4-positive cells in primary peripheral blood mononuclear cells and Jurkat T cells. However, angiotensin II significantly increased the rate of CX3CR1-positive THP-1 cells. This effect was not attenuated by the pre-incubation of THP-1 cells with the AT-1 receptor blocker losartan, suggesting that this was not an AT-1-mediated effect. Angiotensin I and II had no effect on fluorescence intensity and the rate of CCR5- and CXCR4-positive THP-1 cells. In conclusion, angiotensin II increases the rate of CX3CR1-positive THP-1 cells. By extrapolating this in vitro observation to disease mechanisms, we speculate that angiotensin II induces up-regulation of CX3CR1 and promotes firm adhesion of circulation CX3CR1-positive monocytes on CX3CL1 expressing endothelial cells inducing vascular inflammation and atherogenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19915801     DOI: 10.1007/s11239-009-0424-1

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  27 in total

Review 1.  Jurkat T cells and development of the T-cell receptor signalling paradigm.

Authors:  Robert T Abraham; Arthur Weiss
Journal:  Nat Rev Immunol       Date:  2004-04       Impact factor: 53.106

2.  Angiotensin II-induced mononuclear leukocyte interactions with arteriolar and venular endothelium are mediated by the release of different CC chemokines.

Authors:  Teresa Mateo; Yafa Naim Abu Nabah; May Abu Taha; Manuel Mata; Miguel Cerdá-Nicolás; Amanda E I Proudfoot; Rolf A K Stahl; Andrew C Issekutz; Julio Cortijo; Esteban J Morcillo; Peter J Jose; Maria-Jesus Sanz
Journal:  J Immunol       Date:  2006-05-01       Impact factor: 5.422

3.  Angiotensin II induces c-fos mRNA in aortic smooth muscle. Role of Ca2+ mobilization and protein kinase C activation.

Authors:  M B Taubman; B C Berk; S Izumo; T Tsuda; R W Alexander; B Nadal-Ginard
Journal:  J Biol Chem       Date:  1989-01-05       Impact factor: 5.157

4.  Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney.

Authors:  Marta Ruiz-Ortega; Mónica Ruperez; Oscar Lorenzo; Vanesa Esteban; Julia Blanco; Sergio Mezzano; Jesus Egido
Journal:  Kidney Int Suppl       Date:  2002-12       Impact factor: 10.545

5.  Obesity is associated with tissue-specific activation of renal angiotensin-converting enzyme in vivo: evidence for a regulatory role of endothelin.

Authors:  M Barton; R Carmona; H Morawietz; L V d'Uscio; W Goettsch; H Hillen; C C Haudenschild; J E Krieger; K Münter; T Lattmann; T F Lüscher; S Shaw
Journal:  Hypertension       Date:  2000-01       Impact factor: 10.190

Review 6.  Chemokines and atherosclerosis.

Authors:  T J Reape; P H Groot
Journal:  Atherosclerosis       Date:  1999-12       Impact factor: 5.162

7.  ACE inhibition lowers angiotensin II-induced chemokine expression by reduction of NF-kappaB activity and AT1 receptor expression.

Authors:  Alexander Schmeisser; Oliver Soehnlein; Thomas Illmer; Hanns-Martin Lorenz; Saeed Eskafi; Olaf Roerick; Christoph Gabler; Ruth Strasser; Werner G Daniel; Christoph D Garlichs
Journal:  Biochem Biophys Res Commun       Date:  2004-12-10       Impact factor: 3.575

Review 8.  Is angiotensin-II an endogenous pro-inflammatory molecule?

Authors:  Undurti N Das
Journal:  Med Sci Monit       Date:  2005-04-28

9.  Establishment and characterization of a human acute monocytic leukemia cell line (THP-1).

Authors:  S Tsuchiya; M Yamabe; Y Yamaguchi; Y Kobayashi; T Konno; K Tada
Journal:  Int J Cancer       Date:  1980-08       Impact factor: 7.396

10.  CX3CR1 receptor is up-regulated in monocytes of coronary artery diseased patients: impact of pre-inflammatory stimuli and renin-angiotensin system modulators.

Authors:  Stavros Apostolakis; Elias Krambovitis; Zaharenia Vlata; Georgios E Kochiadakis; Stavroula Baritaki; Demetrios A Spandidos
Journal:  Thromb Res       Date:  2007-05-23       Impact factor: 3.944

View more
  6 in total

1.  Thrombospondin-1 and angiotensin II inhibit soluble guanylyl cyclase through an increase in intracellular calcium concentration.

Authors:  Saumya Ramanathan; Stacy Mazzalupo; Scott Boitano; William R Montfort
Journal:  Biochemistry       Date:  2011-08-16       Impact factor: 3.162

2.  Role of fractalkine/CX3CR1 interaction in light-induced photoreceptor degeneration through regulating retinal microglial activation and migration.

Authors:  Meng Zhang; Gezhi Xu; Wei Liu; Yingqin Ni; Wenting Zhou
Journal:  PLoS One       Date:  2012-04-19       Impact factor: 3.240

Review 3.  The CXCL12/CXCR4 chemokine ligand/receptor axis in cardiovascular disease.

Authors:  Yvonne Döring; Lukas Pawig; Christian Weber; Heidi Noels
Journal:  Front Physiol       Date:  2014-06-11       Impact factor: 4.566

4.  Renovascular hypertension increases serum TNF and CX3CL1 in experimental Trypanosoma cruzi infection.

Authors:  M C Silva; M A Azevedo; V P Figueiredo; M R Moura Junior; D Coelho Junior; P M Martinelli; R P Machado; A C Alzamora; A Talvani
Journal:  Braz J Med Biol Res       Date:  2018-03-26       Impact factor: 2.590

Review 5.  Regulation and function of CX3CR1 and its ligand CX3CL1 in kidney disease.

Authors:  Sibylle von Vietinghoff; Christian Kurts
Journal:  Cell Tissue Res       Date:  2021-05-19       Impact factor: 4.051

6.  Opposite effect of angiotensin receptor blockade on CXCL8 production and CXCR1/2 expression of angiotensin II-treated THP-1 monocytes.

Authors:  Konstantina Vogiatzi; Stavros Apostolakis; Zaharenia Vlata; Elias Krabovitis; Demetrios A Spandidos
Journal:  Exp Ther Med       Date:  2013-01-21       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.